[{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ring","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ ViiV Healthcare"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ring","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health"}]

Find Clinical Drug Pipeline Developments & Deals for Dapivirine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 13, 2022

                          Lead Product(s) : Dapivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The dapivirine ring received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use through EU-M4all procedure, Prequalification from the World Health Organization (WHO), a WHO recommendation for use and ...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 11, 2022

                          Lead Product(s) : Dapivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : ViiV Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Lead Product(s) : Dapivirine

                          Therapeutic Area : Hematology

                          Study Phase : Phase I/ Phase II

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 13, 2021

                          Lead Product(s) : Dapivirine

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : EMA’s human medicines committee has adopted a positive opinion for Dapivirine Vaginal Ring used to reduce the risk of infection with the human immunodeficiency virus type 1 (HIV-1), in combination with safer sex practices when oral pre-exposure prophyl...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 24, 2020

                          Lead Product(s) : Dapivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank